Cargando…
Silver-Enhanced In Situ Hybridization as an Alternative to Fluorescence In Situ Hybridization for Assaying HER2 Amplification in Clinical Breast Cancer
PURPOSE: Valid determination of HER2 status is a prerequisite to establish an adequate treatment strategy for breast cancer patients, regardless of the disease stage. The goal of this study was to examine the feasibility of the newly developed silver-enhanced in situ hybridization (SISH) technique a...
Autores principales: | Park, Kyeongmee, Han, Sehwan, Kim, Jung-Yeon, Kim, Hyun-Jung, Kwon, Ji Eun, Gwak, Geumhee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Breast Cancer Society
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3268923/ https://www.ncbi.nlm.nih.gov/pubmed/22323913 http://dx.doi.org/10.4048/jbc.2011.14.4.276 |
Ejemplares similares
-
Predictors of Recurrent Ductal Carcinoma In Situ after Breast-Conserving Surgery
por: Kim, Jung Yeon, et al.
Publicado: (2016) -
The effect of an alternative chromosome 17 probe on fluorescence in situ hybridization for the assessment of HER2 amplification in invasive breast cancer
por: Xu, Zhigao, et al.
Publicado: (2019) -
Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization for Low and High Throughput HER2 Genetic Testing
por: Poulsen, Tim S., et al.
Publicado: (2013) -
HER2 Status by Standardized Immunohistochemistry and Silver-Enhanced In Situ Hybridization in Korean Breast Cancer
por: Bae, Young Kyung, et al.
Publicado: (2012) -
Determination of the HER2 amplification status by in situ fluorescent hybridization and concordance with immunohistochemistry for breast cancer samples in Colombia
por: Plata, Adriana, et al.
Publicado: (2013)